JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Profita, M.
Right arrow Articles by Vignola, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Profita, M.
Right arrow Articles by Vignola, A. M.

Vol. 300, Issue 3, 868-875, March 2002

Leukotriene B4 Production in Human Mononuclear Phagocytes Is Modulated by Interleukin-4-Induced 15-Lipoxygenase

Mirella Profita, Angelo Sala , Liboria Siena, Peter M. Henson, Robert C. Murphy, Alessandra Paternò, Anna Bonanno, Loredana Riccobono, Angela Mirabella, Giovanni Bonsignore and Antonio M. Vignola

Istituto di Fisiopatologia Respiratoria, Consiglio Nazionale delle Ricerche, Palermo, Italy (M.P., L.S., A.P., A.B., L.R., G.B.); Dipartimento di Scienze Famacologiche, Università di Milano, Milan, Italy (A.S.); National Jewish Medical and Research Center, Denver, Colorado (A.S., P.M.H., R.C.M.); and Istituto di Medicina Generale e Pneumologie, Università di Palermo, Palermo, Italy (A.M., A.M.V.).

The aim of this study was to evaluate the consequences of interleukin (IL)-4-induced 15-lipoxygenase (15-LO) expression on leukotriene B4 (LTB4) synthesis in human monocytes. Human monocytes incubated for 24, 48, and 72 h with IL-4 (10 ng/ml) were stimulated with Ca2+-ionophore A23187 (calcimycin; 5 µM) or opsonized zymosan. 15(S)-hydroxyeicosatetraenoic acid [15(S)-HETE], LTB4, and arachidonic acid (AA) release were measured by high-performance liquid chromotography/radioimmunoassay, liquid chromotography/tandem mass spectrometry (LC/MS/MS), or gas chromatography/mass spectrometry. 15-LO activity was evaluated in AA-treated monocytes. 15-LO, 5-lipoxygenase (5-LO) and 5-LO activating protein (FLAP) expression were analyzed by reverse transcription-polymerase chain reaction. Neutrophil chemotactic activity was evaluated using a microtaxis chamber assay. A23187-induced synthesis of 15(S)-HETE was significantly increased after treatment with IL-4 (10 ng/ml) for 48 and 72 h (p < 0.001). Concomitant decrease of LTB4 release was observed after 72 h of incubation with IL-4 (p < 0.001). LC/MS/MS analysis confirmed the production of 15(S)-HETE and the significant inhibition of LTB4 synthesis in IL-4-treated monocyte after challenge with opsonized zymosan. IL-4 treatment induced 15-LO enzymatic activity as well as 15-LO mRNA, but did not affect either 5-LO or FLAP mRNA expression in monocytes. Supernatant from IL-4-treated monocytes showed significantly lower neutrophil chemotactic activity than controls. 15(S)-HETE significantly inhibited LTB4 production induced by A23187-stimulated human monocytes without affecting AA release. IL-4-induced expression of 15-LO in monocytes caused a significant reduction of LTB4 production. Whereas this effect did not reflect changes in 5-LO and FLAP mRNA expression, synthetic 15(S)-HETE was able to significantly inhibit the synthesis of LTB4, without affecting AA release.


0022-3565/02/3003-0868$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
JAMAHome page
H. Hakonarson, S. Thorvaldsson, A. Helgadottir, D. Gudbjartsson, F. Zink, M. Andresdottir, A. Manolescu, D. O. Arnar, K. Andersen, A. Sigurdsson, et al.
Effects of a 5-Lipoxygenase-Activating Protein Inhibitor on Biomarkers Associated With Risk of Myocardial Infarction: A Randomized Trial
JAMA, May 11, 2005; 293(18): 2245 - 2256.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
F. R. Hirsch and S. M. Lippman
Advances in the Biology of Lung Cancer Chemoprevention
J. Clin. Oncol., May 10, 2005; 23(14): 3186 - 3197.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
R. Ramoner, T. Putz, H. Gander, A. Rahm, G. Bartsch, C. Schaber, and M. Thurnher
Dendritic-cell activation by secretory phospholipase A2
Blood, May 1, 2005; 105(9): 3583 - 3587.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. K. Yu, P. J. Moos, P. Cassidy, M. Wade, and F. A. Fitzpatrick
Conditional Expression of 15-Lipoxygenase-1 Inhibits the Selenoenzyme Thioredoxin Reductase: MODULATION OF SELENOPROTEINS BY LIPOXYGENASE ENZYMES
J. Biol. Chem., July 2, 2004; 279(27): 28028 - 28035.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
B. Xu, A. Bhattacharjee, B. Roy, G. M. Feldman, and M. K. Cathcart
Role of Protein Kinase C Isoforms in the Regulation of Interleukin-13-induced 15-Lipoxygenase Gene Expression in Human Monocytes
J. Biol. Chem., April 16, 2004; 279(16): 15954 - 15960.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. E. Kolodsick, G. B. Toews, C. Jakubzick, C. Hogaboam, T. A. Moore, A. McKenzie, C. A. Wilke, C. J. Chrisman, and B. B. Moore
Protection from Fluorescein Isothiocyanate-Induced Fibrosis in IL-13-Deficient, but Not IL-4-Deficient, Mice Results from Impaired Collagen Synthesis by Fibroblasts
J. Immunol., April 1, 2004; 172(7): 4068 - 4076.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
P. Chanez, C. Bonnans, C. Chavis, and I. Vachier
15-Lipoxygenase: A Janus Enzyme?
Am. J. Respir. Cell Mol. Biol., December 1, 2002; 27(6): 655 - 658.
[Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.